Philanthropy-Backed Accelerator Advances Cancer Therapies
Three teams of Dartmouth researchers have been selected to receive the first awards from the Dartmouth Innovations Accelerator for Cancer. (Source: News at Dartmouth Medical School)
Source: News at Dartmouth Medical School - April 15, 2021 Category: Hospital Management Authors: NonPerson Geisel Web Service Acct Tags: News Press Release Source Type: news

Canon Medical, RaySearch expand partnership
Canon Medical Systems USA said it is expanding its partnership with RaySearc...Read more on AuntMinnie.comRelated Reading: Canon nabs top award from IMV's ServiceTrak Canon expands utility of AiCE in MRI Sales of CT and x-ray help Canon 2020 results RaySearch, TAE Life Sciences partner on cancer therapy RaySearch unveils new RayStation release RaySearch, Varian partner to track radiation therapy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 15, 2021 Category: Radiology Source Type: news

Resilient Oregon: Insights from the Children's Cancer Therapy Development Institute
(Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 5, 2021 Category: Biotechnology Source Type: news

UCLA researchers receive $6 million from NIH to explore new pancreatic cancer therapies
A team of researchers from theUCLA Jonsson Comprehensive Cancer Center has been awarded two research grants totaling $6 million from the National Institutes of Health to identify new ways to treat pancreatic cancer.Pancreatic cancer is the third leading cause of cancer-related mortality in the United States, accounting for more than 47,000 deaths annually. Only 1 in 10 people diagnosed with this particularly aggressive disease live beyond five years, and most therapies — including conventional chemotherapies, targeted therapies and immunotherapies — are unsuccessful in treating it.“Pancreatic cancer is on...
Source: UCLA Newsroom: Health Sciences - March 25, 2021 Category: Universities & Medical Training Source Type: news

UCLA team receives $6 million from NIH to explore new pancreatic cancer therapies
(University of California - Los Angeles Health Sciences) A team of researchers from the UCLA Jonsson Comprehensive Cancer Center has been awarded two research grants totaling $6 million from the National Institutes of Health to identify new ways to treat pancreatic cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 25, 2021 Category: Cancer & Oncology Source Type: news

Do you know the way to Berkelium, Californium?
(DOE/Lawrence Berkeley National Laboratory) Scientists at Berkeley Lab have demonstrated how to image samples of heavy elements as small as a single nanogram. The new approach will help scientists advance new technologies for medical imaging and cancer therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 24, 2021 Category: Cancer & Oncology Source Type: news

Deactivating cancer cell gene boosts immunotherapy for head and neck cancers
By targeting an enzyme that plays a key role in head and neck cancer cells, researchers from theUCLA School of Dentistry were able to significantly slow the growth and spread of tumors in mice and enhance the effectiveness of an immunotherapy to which these types of cancers often become resistant.Their findings,  published online in the journal Molecular Cell, could help researchers develop more refined approaches to combatting highly invasive head and neck squamous cell cancers, which primarily affect the mouth, nose and throat.Immunotherapy, which is used as a clinical treatment for various cancers, harnesses t...
Source: UCLA Newsroom: Health Sciences - March 23, 2021 Category: Universities & Medical Training Source Type: news

New anti-cancer therapy: Converting glioma cells into neurons
(Guangdong-Hongkong-Macau Institute of CNS Regeneration,Jinan University) Glioma is a fatal neurological disorder that has limited interventional treatment, despite extensive research over the past several decades. A research team led by Dr. Gong Chen,has developed a novel gene therapy to reprogram glioma cells into functional neurons, shedding new light on glioma treatment. The work has been published in Cancer Biology& Medicine on March 22, 2021 (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 23, 2021 Category: Cancer & Oncology Source Type: news

Jose Baselga, Renowned Oncologist, Dies at 61
The cancer researcher and executive vice president of AstraZeneca's oncology research and development is well known for his role in the development of pivotal breast cancer therapies. (Source: The Scientist)
Source: The Scientist - March 22, 2021 Category: Science Tags: News & Opinion Source Type: news

Sirtex Medical announces new SIR-Spheres(R) DOORwaY-90 Study: The first prospective multicenter U.S.-based trial for registration as first-line treatment for hepatocellular carcinoma
WOBURN, Mass., March 22, 2021 -- (Healthcare Sales & Marketing Network) -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced full FDA approval of the DOORwaY90 Study, a trial evaluating the safety an... Devices, Oncology Sirtex Medical, SIR-Spheres, Y-90 resin microspheres, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2021 Category: Pharmaceuticals Source Type: news

Stimulating the immune system to fight cancer
(Max Planck Institute of Molecular Physiology) Cancer cells have evolved mechanisms to escape the body's immune defense. Agents that prevent immune escape are attractive targets for the development of new cancer therapies. Scientists led by Prof. Herbert Waldmann and Dr. Slava Ziegler at the Max Planck Institute of Molecular Physiology in Dortmund have now developed a new cell-based test system to identify immunoregulatory modulators. Screening a library of over 150,000 substances revealed several potent substances with unprecedented structure. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 17, 2021 Category: International Medicine & Public Health Source Type: news

Immuno-PET shows tumor response to therapy
Immuno-PET imaging illuminates a tumor's response to therapy, which could translat...Read more on AuntMinnie.comRelated Reading: ARTMS gets funds to develop Zr-89 for PET Zr-89 immuno-PET could help predict cancer therapy outcomes Immuno-PET could aid patients with inflammatory diseases Immuno-PET tracer offers hope for early cancer treatment Immuno-PET radiotracers may aid cancer treatment (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 15, 2021 Category: Radiology Source Type: news

Penn spinout Linnaeus Therapeutics gets key FDA designation
The company is developing new cancer therapies based on the discoveries of a Penn researcher. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 12, 2021 Category: American Health Authors: John George Source Type: news

Adhesion, contractility enable metastatic cells to go against the grain
(University of California - San Diego) Bioengineers at the University of California San Diego and San Diego State University have discovered a key feature that allows cancer cells to break from typical cell behavior and migrate away from the stiffer tissue in a tumor, shedding light on the process of metastasis and offering possible new targets for cancer therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 9, 2021 Category: Cancer & Oncology Source Type: news

A biosensor for measuring extracellular hydrogen peroxide concentrations
(Kanazawa University) Researchers at Kanazawa University report inBiosensors and Bioelectronics a successful test of a sensor for measuring hydrogen peroxide concentrations near cell membranes. The sensor has the potential to become a tool for new cancer therapies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 8, 2021 Category: International Medicine & Public Health Source Type: news

Inovio spinout Geneos closes $12M financing round to advance personalized cancer therapy
The Montgomery County biopharmaceutical company's initial target is a type of liver cancer known as advanced hepatocellular carcinoma. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 4, 2021 Category: Biotechnology Authors: John George Source Type: news

Finding their comfort zone
(George Mason University) A Mason Engineering researcher has discovered that artificial microswimmers accumulate where their speed is minimized, an idea that could have implications for improving the efficacy of targeted cancer therapy. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 26, 2021 Category: Biology Source Type: news

University of Chicago study uncovers inhibitory role of 'Ter cells' in cancer therapies
(University of Chicago Medical Center) A multidisciplinary research team based at the University of Chicago Medicine has recently focused on a type of cell that releases a protein that enhances resistance to cancer therapies and promotes tumor progression. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 24, 2021 Category: Cancer & Oncology Source Type: news

Trial of Gene Therapy for Sickle Cell Disease Halted
TUESDAY, Feb. 23, 2021 -- A clinical trial of a new gene therapy for sickle cell disease that has shown promise has been halted after two participants were diagnosed with cancer. Therapy developer Bluebird Bio said a patient who was treated five... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 23, 2021 Category: Pharmaceuticals Source Type: news

Health Highlights: Feb. 23, 2021
  Trial of Gene Therapy for Sickle Cell Disease Halted A clinical trial of a new gene therapy for sickle cell disease that's shown promise has been halted after two participants were diagnosed with cancer. Therapy developer Bluebird Bio said... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 23, 2021 Category: General Medicine Source Type: news

Good cop, bad cop
(Champalimaud Centre for the Unknown) Serendipitous observation leads to novel insight into how cancer-immune crosstalk can either promote or suppress tumour growth. Ultimately, this study's results may help develop novel cancer therapies as well as an assay to select patients for immunotherapy treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 19, 2021 Category: International Medicine & Public Health Source Type: news

Insight Into Why a Prostate Cancer Therapy Works Better for Black Men
(Source: Fertility News - Doctors Lounge)
Source: Fertility News - Doctors Lounge - February 17, 2021 Category: Reproduction Medicine Tags: Nursing, Oncology, Pharmacy, Reproductive Medicine, Research, Urology, News, Source Type: news

Insight Into Why a Prostate Cancer Therapy Works Better for Black Men
WEDNESDAY, Feb. 17, 2021 -- Higher levels of a certain type of immune cell may explain why immunotherapy for prostate cancer is more effective in Black men than in white men, researchers say. The finding could lead to immunotherapy-based precision... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 17, 2021 Category: General Medicine Source Type: news

Cosmetic laser may boost effectiveness of certain anti-cancer therapies
(Massachusetts General Hospital) In mice treated with cancer immunotherapy, shining a cosmetic laser on a tumor boosted the therapy's effectiveness. The strategy stimulated the immune system to attack nonmutated proteins on the tumor. The findings may help investigators make cancer immunotherapy effective against currently incurable cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 17, 2021 Category: Cancer & Oncology Source Type: news

Medication-based starvation of cancer cells
(Technical University of Munich (TUM)) Immunomodulatory drugs, including the Contergan derivatives lenalidomide and pomalidomide have significantly improved the therapy of hematologic malignancies such as multiple myeloma. Researchers at the Technical University of Munich (TUM) have now further decoded the mode of action in this class of medications. At the same time, they identified new innovative targeted cancer therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 12, 2021 Category: Cancer & Oncology Source Type: news

Chemotherapy and hearing loss: Until now, an unquantified risk
(Children's Hospital Los Angeles) Researchers conduct largest-ever study of cisplatin-induced hearing loss in pediatric patients. The study gives oncologists, for the first time, real-world risk benchmarks for hearing loss due to cancer therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 11, 2021 Category: Cancer & Oncology Source Type: news

Nano-MRI outduels PSMA-PET/CT for prostate cancer
Clinicians looking to accurately classify suspicious lymph nodes in prostat...Read more on AuntMinnie.comRelated Reading: FDA makes history with approval of Ga-68 PSMA-11 PET PET/CT with Ga-68 tracer better for cancer patients PSMA-PET/CT most effective for recurrent prostate cancer Ga-68 PSMA PET with CT, MRI proves safe and accurate SNMMI: PSMA-PET helps guide prostate cancer therapy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 5, 2021 Category: Radiology Source Type: news

Biocon Biologics to provide cancer biosimilars to 30 countries in Africa, Asia
Biocon Biologics said it aims to deliver substantial savings to healthcare systems by enhancing access and availability of these high-quality and affordable biosimilar cancer therapies in 25 countries in Africa and five countries in Asia, which are currently covered under CAP. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 4, 2021 Category: Pharmaceuticals Source Type: news

Intensity not paramount for physical training during cancer therapy
(Uppsala University) People receiving treatment for cancer are known to feel better with physical training. But does it make any difference how vigorously they exercise? A new study by researchers at Uppsala University shows that whether the training is intensive or rather less strenuous, its effect is roughly the same. The results are published in the journalScandinavian Journal of Medicine and Science in Sports. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 3, 2021 Category: Cancer & Oncology Source Type: news

COVID-19 vaccination programme, RCGP (updated 28th January 2021)
The latest updates on the COVID-19 vaccine, including: COVID-19 Vaccination FAQs SARS-CoV-2 Vaccination #RCGPLive: COVID-19 vaccination in general practice Clinician FAQs and guidance on COVID-19 vaccine for patients receiving Systemic Anti-Cancer Therapy (SACT) Managing anaphylaxis: guidance for GPs delivering the COVID-19 vaccine (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 29, 2021 Category: Consumer Health News Source Type: news

Scientists spotted RPS-12 protein as a potential target for anti-cancer therapy
(Far Eastern Federal University) Using the developing eye of the fruit fly as a test platform, researchers found that RPS-12 protein overproduction appears to trigger triple-negative breast cancer and possibly some other malignancies. The protein indirectly switches on an important inracellular signaling pathway active while the embryo develops and shut down in healthy cells of adults. Far Eastern Federal University (FEFU), the University of Geneva, and the Institute of Protein Research (Russia) scientists addressed the problem in Scientific Reports. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 29, 2021 Category: Cancer & Oncology Source Type: news

Pharmaceutical research: when active substance and target protein 'embrace' each other
(Goethe University Frankfurt) Scientists at Goethe University Frankfurt, together with colleagues from Darmstadt, Heidelberg, Oxford and Dundee (UK), have investigated how the fit of potent inhibitors to their binding sites can be optimised so that they engage longer with their target proteins. Long target residency has been associated with more efficient pharmacological responses e.g. in cancer therapy. In future, the researchers want to use computer simulations to predict the residence time of inhibitors during drug development. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 28, 2021 Category: Biology Source Type: news

Humanizing yeast ORC sheds light on cancer therapy and human development
(Hong Kong University of Science and Technology) Researchers from the HKSUST and the HKU recently demonstrated that the selectivity determinant of Origin Recognition Complex for DNA binding lies in a 19-amino acid insertion helix in the Orc4 subunit, which is present in yeast but absent in human. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 27, 2021 Category: Biology Source Type: news

AACR and MPM announce three grants to support transformative cancer research
(American Association for Cancer Research) Three grants for research that could transform cancer therapies have been awarded by the AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants Program, an innovative partnership between the American Association for Cancer Research (AACR) and the UBS Oncology Impact Fund (OIF) managed by MPM Capital. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 21, 2021 Category: International Medicine & Public Health Source Type: news

Gold nanoparticles more stable by putting rings on them
(Hokkaido University) Hokkaido University scientists have found a way to prevent gold nanoparticles from clumping, which could help towards their use as an anti-cancer therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 21, 2021 Category: Cancer & Oncology Source Type: news

Synthetic biomaterial guides cancer therapy to hidden tumors
Advance opens up new possibilities for CAR T-cell therapy to treat a variety of cancers (Source: UCSF School of Pharmacy News)
Source: UCSF School of Pharmacy News - January 20, 2021 Category: Universities & Medical Training Source Type: news

Ultra-small nanomedicines which stably deliver oligonucleotides to refractory cancers
(Innovation Center of NanoMedicine) Ultra-small nanomedicines with a size of ca. 18 nm were fabricated by dynamic ion-pairing between Y-shaped block copolymers and oligonucleotide drugs. Chemically modified and double-stranded oligonucleotides dramatically enhanced the stability of the ultra-small nanomedicines in the bloodstream. The size allows for high permeability in cancer tissues by slipping through the cracks in tumor vasculatures and stromal tissues. Clinical trials and preclinical studies using the developed ultra-small nanomedicines are proceeding for refractory cancer therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 19, 2021 Category: Cancer & Oncology Source Type: news

Prelude, Onconova plan multimillion-dollar stock sales
Two Philadelphia-area biopharmaceutical companies focused on developing cancer therapies expect to raise a total of nearly $160 million from stock offerings Monday. The majority of the funds are expected to be raised by Prelude Therapeutics (NASDAQ: PRLD), a precision oncology company based in Wilmington. Prelude is selling 2.2 million shares of its voting common stock and 292,000 shares of its non-voting common stock, each at a public offering price of $60 p er share. The gross proceeds from the… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 11, 2021 Category: Pharmaceuticals Authors: John George Source Type: news

AI Drug Discovery Startup Valo Raises $190 Million And Unveils Cancer Therapy Programs
The Boston-based company aims to accelerate the drug discovery process for cancer therapies that are both more effective and less toxic. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 11, 2021 Category: Pharmaceuticals Authors: Alex Knapp, Forbes Staff Tags: Science /science Innovation /innovation Healthcare /healthcare AI /ai Editors' Pick editors-pick technology alexknappblog Source Type: news

Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies
OXFORD, England, Jan. 7, 2021 -- (Healthcare Sales & Marketing Network) -- Theolytics, a UK biotech harnessing viruses to combat cancer, today announced the closing of a US $6.8 million (UK £5 million) Series A round. The round was co-led by Epidare... Biopharmaceuticals, Oncology, Venture Capital Theolytics, oncolytic virus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 7, 2021 Category: Pharmaceuticals Source Type: news

Loss of anti-tumor protein may cause resistance to certain cancer therapies
(Penn State) The absence of a protein that works to prevent tumor formation may explain why some patients are resistant to a common cancer therapy, according to Penn State College of Medicine researchers. They said that testing cancers for the presence of this protein may help clinicians identify patients who may be resistant to or relapse when treated with the therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 21, 2020 Category: Cancer & Oncology Source Type: news

Karyopharm Announces FDA Approval of Xpovio (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
NEWTON, Mass., Dec. 18, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial stage pharmaceutical company pioneering novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 18, 2020 Category: Drugs & Pharmacology Source Type: news

Palliative care improves quality of life for patients with advanced blood cancer
(Massachusetts General Hospital) A first-of-its-kind intervention integrating palliative care early in the course of cancer therapy for patients with advanced acute myeloid leukemia (AML), a highly aggressive cancer of the blood and bone marrow, resulted in substantial improvements in patients' quality of life, mood and end-of-life care, a team of investigators has found. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 17, 2020 Category: Cancer & Oncology Source Type: news

TRIUMF enters collaboration with fusion pharmaceuticals to boost production of actinium-225
(PR Associates) TRIUMF, Canada's particle accelerator centre, today announced it has entered into a collaboration agreement with Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Under the agreement, Fusion will provide a financial investment enabling TRIUMF to upgrade its actinium-225 production infrastructure, and in return will receive preferred access to actinium-225, a rare medical isotope that shows great promise in new, cutting-edge cancer therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 16, 2020 Category: Cancer & Oncology Source Type: news

Report: More than 1,300 medicines and vaccines in development to help fight cancer
Over the last 30 years, significant progress has been made in the fight against cancer. Researchers have expanded their understanding of how cancer develops and how to target medicines for specific cancer types. Since peaking in 1991, the death rate associated with cancerdeclined by 29%, which translates to 2.9 million fewer cancer deaths. The most recent data shows that between 2016 and 2017 alone, cancer death ratesdeclined by 2.2%, the largest single-year drop ever recorded. Despite the challenges imposed by the COVID-19 pandemic, this momentum continues with biopharmaceutical companies focusing on research and dev...
Source: The Catalyst - December 15, 2020 Category: Pharmaceuticals Tags: Medicines in Development Cancer New Era of Medicine & D Focus Source Type: news

EMA Panel Endorses Approval of Five New Cancer Drugs EMA Panel Endorses Approval of Five New Cancer Drugs
The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing authorization or has given a positive opinion regarding several cancer therapies.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Novel genomic tools increase the accuracy of breast cancer risk assessment
(University of Helsinki) Findings from the FinnGen study encompassing 120,000 women indicate that inherited breast cancer risk should be assessed in an increasingly comprehensive manner. Currently, only individual gene mutations are taken into consideration in breast cancer therapy and prevention. The study demonstrates that more extensive genomic data can be used to identify women who are at high risk of breast cancer with considerably greater accuracy. Such knowledge can especially improve risk assessment among the close relatives of breast cancer patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 14, 2020 Category: International Medicine & Public Health Source Type: news

How AI could make therapeutic decision-making for breast cancer more accurate, affordable
(Salesforce) Deep learning-enabled breast cancer technology could make breast cancer therapy decisions more accurate, affordable and accessible. For newly diagnosed breast cancer, estrogen receptor status (ERS) is a key molecular marker used for prognosis and treatment decisions. This is an expensive, time-consuming process. Here we show that machine learning can determine molecular marker status. Our approach could augment clinicians' capabilities in cancer prognosis and theragnosis by harnessing biological signals imperceptible to the human eye. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2020 Category: International Medicine & Public Health Source Type: news

Despite COVID-19 pandemic first patient undergoes new personalized immunotherapy
(University of California - San Diego) Bernard Thurman was referred to a personalized cancer therapy trial at Moores Cancer Center at UC San Diego Health, a collaboration with the La Jolla Institute for Immunology, the trial employs a patient's immune cells -- specifically tumor infiltrating lymphocytes (TIL) -- to destroy cancer cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2020 Category: Cancer & Oncology Source Type: news

Freiburg researcher Barbara Di Ventura receives two million-euro ERC Consolidator Grant
(University of Freiburg) The Freiburg engineer and biologist Prof. Dr. Barbara Di Ventura receives a Consolidator Grant from the European Research Council (ERC), one of the most prestigious prizes for European researchers, for her project " InCanTeSiMo - Intelligent cancer therapy with synthetic biology methods " . (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 9, 2020 Category: Cancer & Oncology Source Type: news